IDENTIFICATION OF ADDITIONAL CHROMOSOMAL ABNORMALITIES IN Ph-POSITIVE CHRONIC MYELOID LEUKEMIA
Keywords:
The study consisted of analyzing the spectrum of karyotype changes in Ph-positive CML patients.Abstract
chronic myeloid leukemia; Philadelphia chromosome; additional chromosomal abnormalities; tyrosine kinase inhibitor
Downloads
References
Cortes J, Dwyer MEO. Clonal evolution in chron ic myelogenous leukemia. Hematol Oncol Clin N Am. 2004;18:671-684
Cortes J, Talpaz M, Giles F, O’Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003;3794:3800-101.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buch dunger E, Ford JM, Lydon NB, Kantarjian H, Cap deville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyro sine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-7.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buch dunger E, Ford JM, Lydon NB, Kantarjian H, Cap deville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyro sine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-7.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
